Quick Answer
ARS Pharmaceuticals, Inc. reported Net Income of -$171.30 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$171.30M | -2241.8% |
| 2024 | $8.00M | +114.7% |
| 2023 | -$54.37M | -56.8% |
| 2022 | -$34.68M | -71.3% |
| 2021 | -$20.24M | +38.6% |
| 2020 | -$32.95M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$51.15M | -167.4% | -14.0% |
| June 30, 2025 | -$44.88M | -258.6% | -32.2% |
| March 31, 2025 | -$33.94M | -229.8% | -77.4% |
| September 30, 2024 | -$19.13M | -28.7% | -52.8% |
| June 30, 2024 | -$12.52M | +27.9% | -21.6% |
| March 31, 2024 | -$10.29M | +31.2% | +30.8% |
| September 30, 2023 | -$14.87M | -125.8% | +14.4% |
| June 30, 2023 | -$17.37M | -170.6% | -16.1% |
- ARS Pharmaceuticals, Inc. showed a decrease of -2241.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, ARS Pharmaceuticals, Inc.’s net income has declined by 419.9% (from -$32.95 million to -$171.30 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: